Simvastatin Inhibits sPLA2 IIa Expression in Aorta and Myocardium

Archives of Medical Research

Volumn 40, Issue 2, 2009, Pages 67-72

  Wei hua, Li ^a   Chang qing, Sun ^a   Qiang, Xie ^a   Rong, Wu ^a   Kai min, Lin ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Group IIa secretory phospholipase A2 (sPLA2 IIa); Myocardium; Simvastatin; Visceral adipose tissue

Indexed keywords

PHOSPHOLIPASE A2 GROUP II; SIMVASTATIN; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA ATHEROSCLEROSIS; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; HEART MUSCLE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INTRAABDOMINAL FAT; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SMOOTH MUSCLE FIBER;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA; ATHEROSCLEROSIS; CHOLESTEROL; GENE EXPRESSION; GROUP II PHOSPHOLIPASES A2; INTRA-ABDOMINAL FAT; MALE; MYOCARDIUM; MYOCYTES, SMOOTH MUSCLE; RATS; RATS, WISTAR; SIMVASTATIN; TRIGLYCERIDES;

EID: 60349126890     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2008.12.006     Document Type: Article

References (31)

1. 2 predict coronary events in patients with coronary artery disease. Circulation 100 (1999) 1280-1284
2. Six D.A., and Dennis E.A. The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochem Biophys Acta 1488 (2000) 1-19
3. Olsson U., Bondjers G., and Camejo G. Fatty acids modulate the composition of extracellular matrix in cultured human arterial smooth muscle cells by altering the expression of genes for proteoglycan core proteins. Diabetes 48 (1999) 616-622
4. Menschikowski M., Kasper M., Lattke P., et al. Secretory group II phospholipase A2 in human atherosclerotic plaques. Atherosclerosis 118 (1995) 173-181
5. Ivandic B., Castellani L.W., Wang X.P., et al. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol 19 (1999) 1284-1290
6. Menschikowski M., Hagelgans A., and Siegert G. Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?. Prostaglandins Other Lipid Mediat 79 (2006) 1-33
7. Kanters E., Pasparakis M., Gijbels M.J., et al. Inhibition of NF-κB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest 112 (2003) 1176-1185
8. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
9. 2 group IIA on lipoproteins and in atherogenesis. Eur J Clin Invest 32 (2002) 383-393
10. 2 induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler Thromb Vasc Biol 21 (2001) 1053-1058
11. Neuzil J., Upston J.M., Witting P.K., Scott K.F., and Stocker R. Secretory phospholipase A2 and lipoprotein lipase enhance 15-lipoxygenase-induced enzymic and nonenzymic lipid peroxidation in low density lipoproteins. Biochemistry 37 (1998) 9203-9210
12. Hurt-Camejo E., Olsson U., Wiklund O., Bondjers G., and Camejo G. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Arterioscler Thromb Vasc Biol 17 (1997) 1011-1017
13. 2 modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. J Biol Chem 274 (1999) 25913-25920
14. Galeano N.F., Al-Haideri M., Keyserman F., Rumsey S.C., and Deckelbaum R.J. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res 39 (1998) 1263-1263
15. Tabas I., Williams K.J., and Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116 (2007) 1832-1844
16. Romano M., Romano E., Björkerud S., and Hurt-Camejo E. Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries. Arterioscler Thromb Vasc Biol 18 (1998) 519-525
17. Oörni K., Pentikäinen M.O., Ala-Korpela M., and Kovanen P.T. Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions. J Lipid Res 41 (2000) 1703-1714
18. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
19. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med 314 (1986) 448-500
20. Wiklund O., Hulthe J., Bondjers G., and Hurt-Camejo E. Cell adhesion molecules and secretory type II phospholipase A2 in relation to carotid atherosclerosis in patients with hypercholesterolaemia. J Intern Med 249 (2001) 441-449
21. Menschikowski M., Hagelgans A., Heyne B., et al. Statins potentiate the IFN-γ-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells. Biochim Biophys Acta 1733 (2005) 157-1571
22. Kudo I., Murakami M., Hara S., and Inoue K. Mammalian non-pancreatic phospholipases A2. Biochim Biophys Acta 1170 (1993) 217-231
23. Murakami M., Kudo I., and Inoue K. Secretory phospholipases A2. J Lipid Mediat Cell Signal 12 (1995) 119-130
24. Jaulmes A., Janvier B., and Andreani M. Autocrine and paracrine transcriptional regulation of type IIA secretory phospholipase A2 gene in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 25 (2004) 1161-1167
25. Krijnen P.A., Meischl C., Nijmeijer R., Visser C.A., Hack C.E., and Niessen H.W. Inhibition of sPLA2-IIA, C-reactive protein or complement: new therapy for patients with acute myocardial infarction?. Cardiovasc Hematol Disord Drug Targets 6 (2006) 113-123
26. Ouchi N., Kihara S., Funahashi T., et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107 (2003) 671-674
27. Labarrere C.A., and Zaloga G.P. C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med 117 (2004) 499-507
28. Pasceri V., Willerson J.T., and Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
29. Tchernof A., Nolan A., Sites C.K., Ades P.A., and Poehlman E.T. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 105 (2002) 546-569
30. Kopp H.P., Kopp C.W., Festa A., et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 23 (2003) 1042-1047
31. Paradis M.E., Hogue M.O., Mauger J.F., et al. Visceral adipose tissue accumulation, secretory phospholipase A2-IIA and atherogenicity of LDL. Int J Obes (Lond) 30 (2006) 1615-1622